What are the most current biosimilar policy updates regarding psoriatic disease?
British Columbia: BC’s Biosimilar Initiative which was launched in 2019 is being expanded to include adalimumab (i.e., Humira®) biosimilars. During the switch period between April 7th to October 6, 2021, the BC Biosimilar Initiative will continue to offer adalimumab and its biosimilars including Amgevita™, Hadlima®, Hulio®, Hyrimoz®, and Idacio®; however, to maintain PharmaCare coverage, patients who are affected by this policy should obtain a new prescription before the end of the switch period and discuss the biosimilar options with their healthcare provider. BC will also be expanding its program to include Brenzys® and Erelzi™ etanercept biosimilars. For more information click here.
Alberta: The Alberta Biosimilar Initiative has expanded its policy to include the following adalimumab (Humira®) biosimilar drugs: Amgevita™, Hadlima®, Hulio®, Hyrimoz®, and Idacio®. To maintain coverage through the Alberta government-sponsored drug plan, adult patients who are enrolled in the program and currently taking Humira® should contact their healthcare professional to discuss switching to a biosimilar version by May 1, 2022. For more information click here.
New Brunswick: A new Biosimilar initiative has been launched in the province which involves switching patients enrolled in the New Brunswick Drug Plan from originator biologics to their biosimilars. During the switch period of April 21st and November 30th, 2021, transition to biosimilar drugs must be made to maintain coverage under the New Brunswick Drug Plans. Adalimumab (i.e., Humira®) biosimilars include Amgevita™, Hadlima®, Hulio®, Idacio®, Hyrimoz®. Etanercept (i.e., Enbrel®) biosimilars include Brenzys® and Erelzi®. Infliximab (i.e., Remicade® ) biosimilars include Inflectra®, Renflexis™, Avsola™. For more information click here.
Quebec: It has been announced that starting April 12th, 2022, Régie de l'assurance maladie du Québec (RAMQ) will only cover biosimilar drugs, with exceptions. As this initiative is newly emerging, more information will be shared once available.
For resources on talking to your doctor about treatment decisions, visit https://www.canadianpsoriasisnetwork.com/treatment-decisions/